SCHEMBL7947076

SCHEMBL7947076

CCCCOc1ccncc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 11/20 0.81
CYP3A4 P08684 7/20 0.81
LMNA P02545 5/20 0.64
NPC1 O15118 4/20 0.64
KDM4E B2RXH2 2/20 0.64
ALDH1A1 P00352 2/20 0.64
RAB9A P51151 2/20 0.64
HSD17B10 Q99714 2/20 0.64
MAPT P10636 1/20 0.64
TSHR P16473 1/20 0.64
CYP2C9 P11712 8/20 0.60
CYP2C19 P33261 8/20 0.60
CYP1A2 P05177 7/20 0.60
SMN1; SMN2 Q16637 4/20 0.58
NFKB1 P19838 1/20 0.58
NFKB2 Q00653 1/20 0.58
RELA Q04206 1/20 0.58
STAT3 P40763 1/20 0.58
CYP19A1 P11511 7/20 0.58
LTA4H P09960 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22145062 0.93 CYP2D6 (0.71) CYP2D6CYP3A4LMNANPC1KDM4E
SCHEMBL4887124 0.91 CYP2D6 (0.69) CYP2D6CYP3A4LMNANPC1KDM4E
SCHEMBL1573619 0.91 CYP2D6 (0.69) CYP2D6CYP3A4LMNANPC1KDM4E
SCHEMBL1996527 0.91 CYP2D6 (0.69) CYP2D6CYP3A4LMNANPC1KDM4E
SCHEMBL1874710 0.91 CYP2D6 (0.69) CYP2D6CYP3A4LMNANPC1KDM4E
SCHEMBL14129958 0.90 CYP2D6 (1.00) CYP2D6CYP3A4LMNANPC1KDM4E
SCHEMBL11245903 0.88 CYP2D6 (0.64) CYP2D6CYP3A4LMNANPC1KDM4E
SCHEMBL2274822 0.87 CYP2D6 (0.64) CYP2D6CYP3A4LMNANPC1KDM4E
SCHEMBL12743776 0.85 CYP2D6 (0.59) CYP2D6CYP3A4LMNANPC1KDM4E
SCHEMBL26850 0.85 LTA4H (0.70) CYP2D6CYP3A4NPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4318630-B1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY ASAHI CHEMICAL IND (JP) 2025-10-22 EP disclosed
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-01-14 US disclosed
EP-4415105-A2 NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE Asahi Kasei Kabushiki Kaisha (JP) 2024-08-14 EP disclosed
US-20240178452-A1 Nonaqueous Electrolyte Solution and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-05-30 US disclosed
EP-4318630-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY Asahi Kasei Kabushiki Kaisha (JP) 2024-02-07 EP disclosed
CN-117223143-A Nonaqueous electrolyte and nonaqueous secondary battery 旭化成株式会社 2023-12-12 CN disclosed
WO-2023023156-A1 ACID CERAMIDASE INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-02-23 WO disclosed
WO-2022203072-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY 旭化成株式会社 2022-09-29 WO disclosed
US-20220293929-A1 Non-Aqueous Secondary Battery and Non-Aqueous Electrolyte ASAHI KASEI KABUSHIKI KAISHA (JP) 2022-09-15 US disclosed
EP-4009398-A1 NON-AQUEOUS SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTE Asahi Kasei Kabushiki Kaisha (JP) 2022-06-08 EP disclosed
CN-104411311-A Substituted benzamides and their use UNIV LELAND STANFORD JUNIOR 2015-03-11 CN disclosed
CN-103327972-A Substituted benzamides and their uses UNIV LELAND STANFORD JUNIOR 2013-09-25 CN disclosed
US-20110224204-A1 DI-SUBSTITUTED PHENYL COMPOUNDS ENVIVO PHARMACEUTICALS, INC. 2011-09-15 US disclosed
WO-2009158467-A2 DI-SUBSTITUTED PHENYL COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2009-12-30 WO disclosed
CN-1315859-C Lincomycin derivatives possessing antibacterial activity VICURON PHARM INC (US) 2007-05-16 CN disclosed
CN-1681832-A Lincomycin derivatives possessing antibacterial activity VICURON PHARM INC (US) 2005-10-12 CN disclosed
US-4631339-A 1,3,5-triazepinones ELI LILLY AND COMPANY (US) 1986-12-23 US disclosed
US-4514564-A 7β-(2'-(1\",3\",5\"-Triazepin-4\"-one)-2'-(oxime ether)-acetamido)-3-substituted cephalosporins ELI LILLY AND COMPANY (US) 1985-04-30 US disclosed
US-4436912-A 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor ELI LILLY AND COMPANY (US) 1984-03-13 US disclosed
US-4430499-A 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1984-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220293929-A1 Non-Aqueous Secondary Battery and Non-Aqueous Electrolyte CLK2, TYK2, CLK3 CYP2D6 4271/4885CYP3A4 3798/4885LMNA 248/4885
US-20110224204-A1 DI-SUBSTITUTED PHENYL COMPOUNDS PDE10A, PDE1A, PDE12 CYP2D6 261/4885CYP3A4 535/4885LMNA 3685/4885
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte CLK2, TYK2, CLK3 CYP2D6 4271/4885CYP3A4 3798/4885LMNA 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.